Key result
Continuous home inotropic therapy sees rising palliative use in advanced HF despite lacking robust clinical data.
Why the study?
The harm and benefits of inotropes in decompensated HFrEF or advanced HF have been debated for decades, while continuous home inotropic therapy has gained traction as palliative care for patients ineligible for advanced therapies.
Does continuous home inotropic therapy improve symptoms in patients with advanced heart failure who are ineligible for or awaiting mechanical circulatory support or heart transplantation?
Design
Review
Authors
Loading...
May inform palliative strategies in advanced HF; leaves open need for prospective trials on symptom benefit.
Does continuous home inotropic therapy improve symptoms in patients with advanced heart failure who are ineligible for or awaiting mechanical circulatory support or heart transplantation?
Continuous home inotropic therapy is increasingly used for palliative care or as a bridge to advanced therapies in advanced heart failure, though evidence-based clinical data are still needed.
Ahmad et al. (2024) conducted a review in Advanced heart failure with reduced ejection fraction. Inotropic therapy (Dobutamine) was evaluated. Continuous home inotropic therapy is increasingly used for palliative care in advanced heart failure, though evidence-based clinical data are still needed to guide its use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: